



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**THE RELATIONSHIP OF SERUM GROWTH
DIFFERENTIATING FACTOR 15 (GDF 15) TO HEPCIDIN
IN POST TRANSPLANT ADULT EGYPTIAN PATIENTS AND
ITS PROGNOSTIC SIGNIFICANCE**

Thesis

Submitted for Partial Fulfillment of MD Degree
In Clinical Hematology

By

Mohammad Abd-Allah Shazly Hafez
(M.B.,B.Ch. M.sC)

Supervised by

Prof. Dr. Mohamed Osman Azzazi

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Prof. Dr. Amal Mostafa Al Afifi

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Prof. Dr. Hany Mohamed Abd-Allah Hegab

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Assist. Prof. Dr. Amro Mohamed Sedky El-Ghammaz

Professor of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain Shams University

Dr. Mostafa Kamal Helmy El Razzaz

Lecturer of Internal Medicine and Clinical Hematology
Faculty of Medicine - Ain shams University

Faculty of Medicine
Ain Shams University

2021

List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	V
▪ List of Figures	IX
▪ Introduction	1
▪ Aim of the Work	4
▪ Review of Literature	
- Chapter (1): Bone Marrow Transplantation.....	5
- Chapter (2): Growth Differentiating Factor15 (GDF15)	34
- Chapter (3): Hepcidin	45
▪ Subjects and Methods	66
▪ Results	76
▪ Discussion	120
▪ Summary and Conclusion	131
▪ Recommendations	136
▪ References	138
▪ Arabic Summary	--

List of Abbreviations

AI	Anemia of Inflammation
ANC	Absolute Neutrophilic Count
Anti-HJV	Anti-Hemojuvelin Antibody
BCNU	Carmustine
BFU-e	Burst Forming Unit-Erythrocyte
BM	Bone Marrow
BMP	Bone Morphogenetic Protein
BMPR	Bone Morphogenetic Protein Receptor
BMPs	Bone Morphogenetic Proteins
BOS	Bronchiolitis Obliterans Syndrome
BSA	Body Surface Area
Bu	Busulfan
BuCy	Busulfan and Cyclophosphamide
CB	Cord Blood
CD	Cluster of Differentiation
CDAI	Congenital Dyserythropoietic Anemia Type I
CFU-e	Colony Forming Unit-Erythrocyte
CML	Chronic Myeloid Leukemia
CMV	Cytomegallovirus
CNI	Calcineurin Inhibitor
CRC	Colorectal Carcinoma
CXCR4	Chemokine Receptor 4
Cy	Cyclophosphamide
DLI	Donor Lymphocyte Infusion
EBV	Ebstein Barr Virus
EPO	Erythropoietin

List of Abbreviations

ERFE		Erythroferrone
ESA		Erythropoiesis Stimulating Agents
ET		Essential Thrombocythemia
Flu		Fludarabine
FPN		Ferroportin
G-CSF		Granulocyte Colony-Stimulating Factors
GDF		Growth Differentiating Factor 15
GF		Graft Failure
GNR		Gram-Negative Rods
GPC		Gram-Positive Cocci
GVHD		Graft Versus Host Disease
HAMP		Hepcidin Antimicrobial Peptide
HDAC3		Histone Deacetylase 3
HIF		Hypoxia Inducible Factor
HL		Hodgkin Lymphoma
HLA		Human Leukocyte Antigen
HPSCT		Hematopoietic Stem Cell Transplant
HSCT		Hematopoietic Stem Cell Transplantation
HSV		Herpes Simplex Virus
IL		Interleukin
INF-γ		Interferon Gamma
IPS		Idiopathic Pneumonia Syndrome
IRIDA		Iron Refractory Iron Deficiency Anemia
LEA		'Leucémie de l'Enfant et de l'Adolescent' cohort
LSEC		Liver Endothelial Sinusoidal Cells

List of Abbreviations

MDS	Myelodysplastic Syndrome
MIC-1	Macrophage Inhibitory Cytokine 1
MM	Multiple Myeloma
MMR	Measles, Mumps, Rubella
MPN	Myeloproliferative Neoplasm
mRNA	Messenger Ribonucleic Acid
MSCs	Mesenchymal Stromal Cells
MT2	Metallothionein
NGS	Next-Generation Sequencing
NHL	Non-Hodgkin Lymphoma
PB	Peripheral Blood
PCV	Pneumococcal Conjugate
PDGF-BB	Platelet Derived Growth Factor
PFTs	Pulmonary Function Tests
PRES	Posterior Reversible Encephalopathy Syndrome
PTLD	Posttransplantation Lymphoproliferative Disorder
PV	Polycythemia Vera
RIC	Reduced-Intensity Conditioning
SABC	Streptavidin Conjugate
SBT	Sequence-Based Typing
SCID	Severe Combined Immune Deficiency Syndrome
SDF-1	Stromal Cell-Derived Factor-1-Alpha
SOS	Sinusoidal Obstruction Syndrome
SSCP	Single-Strand Conformation Polymorphism
SSO	Sequence-Specific Oligonucleotide Probes

List of Abbreviations

SSP	Sequence-Specific Primers
TBI	Total Body Irradiation
TFR	Transferrin Receptors
TGF-β	Transforming Growth Factor- β
TMB	Tetramethylbenzidine
TMPRSS6	Transmembrane Protease, Serine 6
TNF	Tumor Necrosis Factor
UCB	Umbilical Cord Blood
UDCA	Ursodeoxycholic Acid
US	Ultrasound
VOD	Veno Occlusive Disease
VZV	Varicella Zoster Virus

List of Tables

Table No.	Title	Page
Table (1):	Diagnosis of SOS.....	19
Table (2):	Types of graft failure.....	21
Table (3):	Staging of acute graft versus host disease.....	23
Table (4):	Grading of acute graft versus host disease.....	24
Table (5):	Signs and symptoms of chronic GVHD	25
Table (6):	HCT complications according to transplant phase.....	30
Table (7):	Comparison between autologous and allogenic groups of patients regarding age	77
Table (8):	Comparison between patients with autologous, allogenic BMT and control subjects regarding age and sex	77
Table (9):	Comparison between patients and control subjects regarding the serum level of Ferritin, GDF15 and hepcidin	80
Table (10):	Comparison between both autologous and allogenic groups of patients regarding ferritin	82
Table (11):	Comparison between both autologous and allogenic groups of patients regarding GDF15	83

List of Tables (Continued)

Table No.	Title	Page
Table (12):	Comparison between both autologous and allogenic groups of patients regarding hepcidin	84
Table (13):	Comparison between both autologous and allogenic groups of patients regarding exposure to infections	85
Table (14):	The mean values of different ranges of CBC, biochemical results, Dose of stem cells and engraftment dates in both autologous and allogenic groups	87
Table (15):	Number of patients did allogenic BMT	
Table (16):	Different conditioning regimens in allogenic transplanted patients.....	89
Table (17):	The number of patients showed acute and chronic GVHD.....	89
Table (18):	Correlation between gdf15, hepcidin and ferritin levels in allogenic transplanted patients	91
Table (19):	Correlation between age, CBC, biochemical results, date of engraftment and dose of stem cells and ferritin, GDF and hepcidin levels in allogenic transplanted patients.....	94

List of Tables (Continued)

Table No.	Title	Page
Table (20):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patient regarding bacterial infections	102
Table (21):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patient regarding viral infections	102
Table (22):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patients regarding acute GVHD	103
Table (23):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patients regarding chronic GVHD.....	105
Table (24):	Number of patients did autologous BMT....	107
Table (25):	Different conditioning regimens in autologous transplanted patients	108
Table (26):	Correlation between gdf 15, hepcidin and ferritin levels in autologous transplanted patients	108
Table (27):	Correlation between age, CBC, biochemical results, date of engraftment and dose of stem cells and ferritin, GDF and hepcidin levels in autologous BM transplanted patients.....	111

List of Tables (Continued)

Table No.	Title	Page
Table (28):	Comparison between ferritin, GDF15 and hepcidin levels in autologous transplanted patient regarding bacterial infections	118
Table (29):	Comparison between ferritin, GDF15 and hepcidin levels in autologous transplanted patient regarding viral infections	119

List of Figures

Figure No.	Title	Page
Fig. (1):	Schematic representation of mechanisms of anemias with high (left panel) and low hepcidin (right panel)	56
Fig. (2):	Comparison between patients with autologous, allogenic BMT and control subjects regarding age	78
Fig. (3):	Comparison between patients with autologous, allogenic BMT and control subjects regarding sex	79
Fig. (4):	Comparison between patients and control subjects regarding the serum level of Ferritin	80
Fig. (5):	Comparison between patients and control subjects regarding the serum level of GDF15.....	81
Fig. (6):	Comparison between patients and control subjects regarding the serum level of hepcidin	81
Fig. (7):	Comparison between both autologous and allogenic groups of patients regarding ferritin	82
Fig. (8):	Comparison between both autologous and allogenic groups of patients regarding GDF15	83
Fig. (9):	Comparison between both autologous and allogenic groups of patients regarding hepcidin.....	84

List of Figures (Continued)

Figure No.	Title	Page
Fig. (10):	Comparison between both autologous and allogenic groups of patients regarding exposure to infections.....	86
Fig. (11):	Number of patients did allogenic BMT.....	88
Fig. (12):	The number of patients experienced acute and chronic GVHD.....	90
Fig. (13):	Correlation between gdf15 and ferritin levels in allogenic transplanted patients	92
Fig. (14):	Correlation between hepcidin and ferritin levels in allogenic transplanted patients	92
Fig. (15):	Correlation between gdf15 and hepcidin levels in allogenic transplanted patients....	93
Fig. (16):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patients regarding acute GVHD.....	104
Fig. (17):	Comparison between ferritin, GDF15 and hepcidin levels in allogenic transplanted patients regarding chronic GVHD.....	106
Fig. (18):	Number of patients did autologous BMT.....	107